CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet [Yahoo! Finance]
CARGO Therapeutics, Inc. (CRGX)
Company Research
Source: Yahoo! Finance
autoleucel (firi-cel) , in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced disease Most recent, longer-term follow-up data for Stanford Medicine's Phase 1 presented at the 2024 European Hematology Association (EHA) Congress, continued to show promising efficacy, durability and safety profile of firi-cel SAN CARLOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that The Lancet has published favorable data from a Phase 1, single-center clinical study ( NCT04088890 ) by Stanford Medicine (Stanford), evaluating firi-cel, a CD22 CAR T-cell therapy CARGO in-licensed for patients with LBCL whose disease is R/R to
Show less
Read more
Impact Snapshot
Event Time:
CRGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRGX alerts
High impacting CARGO Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CRGX
News
- CARGO Therapeutics, Inc. (NASDAQ: CRGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.MarketBeat
- CARGO Therapeutics, Inc. (NASDAQ: CRGX) had its price target lowered by analysts at Piper Sandler from $37.00 to $34.00. They now have an "overweight" rating on the stock.MarketBeat
- CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- CARGO Therapeutics, Inc. (NASDAQ: CRGX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $33.00 price target on the stock.MarketBeat
- CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The LancetGlobeNewswire
CRGX
Earnings
- 8/12/24 - Beat
CRGX
Sec Filings
- 9/18/24 - Form 144
- 9/18/24 - Form 144
- 8/12/24 - Form 424B3
- CRGX's page on the SEC website